Julianne D. Brooks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julianne D. Brooks has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Lidia Maria Veras Rocha Moura
Department of Neurology, Mass General Brigham, Boston, MA
11 shared publications - Joseph P. Newhouse
Center for Global Health and Mongan Institute, Massachusetts General Hospital Boston Massachusetts USA
8 shared publications - Maria Andrea Donahue
Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts
8 shared publications - Sebastien Haneuse
Harvard T.H. Chan School of Public Health, Boston, USA
7 shared publications - Shuo Sun
Department of Population Health Sciences Weill Cornell Medicine New York New York USA
6 shared publications - Lee H. Schwamm
Department of Neurology, Yale School of Medicine, New Haven, CT (L.H.S.).
4 shared publications
Latest Publications
- Open Access
Patterns of GLP-1 Receptor Agonist Initiation Compared With Other Glucose-Lowering and Anti-Obesity Therapies Among Older Adults
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have rapidly expanded from primarily glucose-lowering agents for type 2 diabetes (T2D) to therapies used across diabetes, obesity, and cardiometabolic disease. Prescribing has risen sharply since 2018, especially with the broader uptake of semaglutide-based products. Still, real-world initiation patterns remain incompletely characterized in older adults with varying levels of cognitive vulnerability and frailty. Methods: We analyzed treatment patterns of GLP-1RA use in a retrospective cohort of adults aged ≥65 years with T2D in a regional healthcare system from 2018 to 2026. We describe the demographic and clinical characteristics of new initiators of GLP-1RAs compared with initiators of alternative therapies, including sodium-glucose cotransporter-2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i). We analyzed a sub-cohort of patients to identify the prevalence of baseline cognitive concerns using a large language model (LLM). We used a LASSO logistic regression to identify important predictors of GLP-1RA initiation compared to other therapies. Results: Of 58,754 adults aged 65 years or older with T2D, 5,095 initiated GLP-1RA, 5,483 initiated a SGLT2 inhibitor, and 1,516 initiated a DPP-4 inhibitor. GLP-1RA initiators were younger (mean 75.2 [SD 4.9] vs 77.7 [6.0] and 79.5 [7.1] years) and less often aged 80 years or older (17.7% vs 35.0% and 47.6%). The largest difference across groups was adiposity: mean BMI was 33.8 (6.2) vs 29.7 (5.7) and 28.6 (5.6) kg/m2 (SMD 0.592), with a BMI of 30 kg/m2 or higher in 72.1% vs 41.9% and 34.0%. Glycemic control was similar (mean HbA1c 7.46% vs 7.38% and 7.70%; SMD 0.165). GLP-1RA initiators were younger; more likely to be overweight; had lower average comorbidity index; and less dementia, heart failure, and renal disease than those initiating alternative therapies. GLP-1RA initiators had fewer hospitalizations 1-year prior to drug initiation. In a LASSO model, BMI greater than 27 kg/m 2 was the strongest predictor of GLP-1RA initiation (positive), followed by baseline congestive heart failure (negative) and baseline hospitalization (negative). Conclusion: In this cohort of older adults, those with T2D who initiated GLP-1RAs were younger and had less comorbidities at baseline compared to initiators of other T2D therapies. Overweight BMI was the strongest predictor of GLP-1RAs initiation, whereas baseline HbA1c was similar across groups, suggesting that the decision to start GLP1-RA is more influenced by adiposity than glycemic control. Our analysis of real-world prescribing patterns appear to be in alignment with guidelines for Type II diabetes treatment 1 , which recommend GLP-1RA treatment for glucose lowering and weight management and SGLT2 treatment in those with risk of cardiovascular disease or heart failure.
Open AccessPatterns of GLP-1 Receptor Agonist Initiation Compared With Other Glucose-Lowering and Anti-Obesity Therapies Among Older Adults
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have rapidly expanded from primarily glucose-lowering agents for type 2 diabetes (T2D) to therapies used across diabetes, obesity, and cardiometabolic disease. Prescribing has risen sharply since 2018, especially with the broader uptake of semaglutide-based products. Still, real-world initiation patterns remain incompletely characterized in older adults with varying levels of cognitive vulnerability and frailty. Methods: We analyzed treatment patterns of GLP-1RA use in a retrospective cohort of adults aged ≥65 years with T2D in a regional healthcare system from 2018 to 2026. We describe the demographic and clinical characteristics of new initiators of GLP-1RAs compared with initiators of alternative therapies, including sodium-glucose cotransporter-2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i). We analyzed a sub-cohort of patients to identify the prevalence of baseline cognitive concerns using a large language model (LLM). We used a LASSO logistic regression to identify important predictors of GLP-1RA initiation compared to other therapies. Results: Of 58,754 adults aged 65 years or older with T2D, 5,095 initiated GLP-1RA, 5,483 initiated a SGLT2 inhibitor, and 1,516 initiated a DPP-4 inhibitor. GLP-1RA initiators were younger (mean 75.2 [SD 4.9] vs 77.7 [6.0] and 79.5 [7.1] years) and less often aged 80 years or older (17.7% vs 35.0% and 47.6%). The largest difference across groups was adiposity: mean BMI was 33.8 (6.2) vs 29.7 (5.7) and 28.6 (5.6) kg/m2 (SMD 0.592), with a BMI of 30 kg/m2 or higher in 72.1% vs 41.9% and 34.0%. Glycemic control was similar (mean HbA1c 7.46% vs 7.38% and 7.70%; SMD 0.165). GLP-1RA initiators were younger; more likely to be overweight; had lower average comorbidity index; and less dementia, heart failure, and renal disease than those initiating alternative therapies. GLP-1RA initiators had fewer hospitalizations 1-year prior to drug initiation. In a LASSO model, BMI greater than 27 kg/m 2 was the strongest predictor of GLP-1RA initiation (positive), followed by baseline congestive heart failure (negative) and baseline hospitalization (negative). Conclusion: In this cohort of older adults, those with T2D who initiated GLP-1RAs were younger and had less comorbidities at baseline compared to initiators of other T2D therapies. Overweight BMI was the strongest predictor of GLP-1RAs initiation, whereas baseline HbA1c was similar across groups, suggesting that the decision to start GLP1-RA is more influenced by adiposity than glycemic control. Our analysis of real-world prescribing patterns appear to be in alignment with guidelines for Type II diabetes treatment 1 , which recommend GLP-1RA treatment for glucose lowering and weight management and SGLT2 treatment in those with risk of cardiovascular disease or heart failure.
- 29 September 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (10)
Post‐Discharge Antiseizure Medication Use and Poststroke Survival: An Emulated Target Trial in Older Adults
Purpose: Levetiracetam is commonly prescribed for seizure prophylaxis after acute ischemic stroke (AIS) and often continued beyond discharge. While its short‐term effectiveness for preventing poststroke seizures is established, it is unclear whether prolonged use improves survival, particularly in older adults. We estimated the effect of continued levetiracetam use on 90‐day mortality among Medicare beneficiaries after AIS. Methods: Using Traditional Medicare claims data (2008–2021), we identified beneficiaries aged ≥ 65 years hospitalized for AIS who initiated outpatient levetiracetam within 90 days of discharge. After 1 month of continued poststroke levetiracetam use (start of follow‐up), we compared 90‐day mortality between patients with a new levetiracetam dispensation within a 14‐day grace period post‐follow‐up and those without one. We performed cloning, censoring, and weighting to address immortal‐time bias and estimated standardized mortality risks, risk differences, and 95% confidence intervals (CIs). Results: Among 3212 eligible beneficiaries, 1779 (55.4%) received a new levetiracetam dispensation within the 14‐day grace period. After adjustment for demographics, hospitalization characteristics, timing of initiation, and comorbidities, continued use was associated with lower 90‐day mortality than discontinuation (53 vs. 62 deaths per 1000; risk difference −9 per 1000; 95% CI: −12, −5). Conclusion: Among older Medicare beneficiaries who initiated levetiracetam after AIS, continued outpatient use was associated with lower short‐term 90‐day mortality, particularly among patients aged ≥ 75 years. These findings should not be interpreted as support for routine or indefinite continuation, because the claims‐based design cannot assess seizure recurrence, functional outcomes, quality of life, treatment indication, or potential neuropsychiatric harms.
- 29 September 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (10)
Post‐Discharge Antiseizure Medication Use and Poststroke Survival: An Emulated Target Trial in Older Adults
Purpose: Levetiracetam is commonly prescribed for seizure prophylaxis after acute ischemic stroke (AIS) and often continued beyond discharge. While its short‐term effectiveness for preventing poststroke seizures is established, it is unclear whether prolonged use improves survival, particularly in older adults. We estimated the effect of continued levetiracetam use on 90‐day mortality among Medicare beneficiaries after AIS. Methods: Using Traditional Medicare claims data (2008–2021), we identified beneficiaries aged ≥ 65 years hospitalized for AIS who initiated outpatient levetiracetam within 90 days of discharge. After 1 month of continued poststroke levetiracetam use (start of follow‐up), we compared 90‐day mortality between patients with a new levetiracetam dispensation within a 14‐day grace period post‐follow‐up and those without one. We performed cloning, censoring, and weighting to address immortal‐time bias and estimated standardized mortality risks, risk differences, and 95% confidence intervals (CIs). Results: Among 3212 eligible beneficiaries, 1779 (55.4%) received a new levetiracetam dispensation within the 14‐day grace period. After adjustment for demographics, hospitalization characteristics, timing of initiation, and comorbidities, continued use was associated with lower 90‐day mortality than discontinuation (53 vs. 62 deaths per 1000; risk difference −9 per 1000; 95% CI: −12, −5). Conclusion: Among older Medicare beneficiaries who initiated levetiracetam after AIS, continued outpatient use was associated with lower short‐term 90‐day mortality, particularly among patients aged ≥ 75 years. These findings should not be interpreted as support for routine or indefinite continuation, because the claims‐based design cannot assess seizure recurrence, functional outcomes, quality of life, treatment indication, or potential neuropsychiatric harms.
- 20 May 2026
- Published by Wiley in Health Services Research
- Vol. 61 (3) , e70133
Gabapentinoid Polypharmacy Among Medicare Beneficiaries During the Poststroke Recovery Period
Objective: To describe patterns of gabapentinoid (Gabapentin and Pregabalin) use and concurrent use with other central nervous system (CNS) acting pain medications (opioids and benzodiazepines) among US Medicare beneficiaries following acute ischemic stroke (AIS). Study Setting and Design: We analyzed new outpatient gabapentinoid prescriptions in older stroke survivors between 2009 and 2022. We calculated the percent of new gabapentinoid initiators within 6 months of stroke discharge and analyzed concurrent pain medications prescribed within 30 days of gabapentinoid initiation. We presented trends and geographic patterns standardized by age, discharge destination, and modified Rankin Scale (mRS) to control for variations in the sample composition by age and stroke severity over time. Data Sources and Analytic Sample: We analyzed a 20% sample of US Medicare beneficiaries aged 65 years or older who were hospitalized for AIS. We included those who met Medicare enrollment criteria, had no prior stroke, no prior gabapentinoid use within 6 months, and were discharged home within 30 days of hospitalization. Principal Findings: Among 153,728 stroke survivors, 4.9% received new gabapentinoid prescriptions within 6 months postdischarge. Of the 7595 gabapentinoid initiators, 1579 (21%) had concurrent opioid and 653 (8.6%) had concurrent benzodiazepine prescriptions. In the sample, the median age was 78 years (Quartile Range: 72–84), 55% were female, and 81% were non‐Hispanic White. The standardized percentage of gabapentinoid initiators increased from 3.8% in 2009 to 5.9% in 2022 (crude: 3.6% in 2009 to 5.8% in 2022). Despite increases in the number of gabapentinoid initiators, the percentage of concurrent opioid users remained low over time, around 1% of the study population. We observed variation in gabapentinoid initiation and concurrent use with opioids by geography. Conclusions: From 2009 to 2022, poststroke gabapentinoid use increased in older adults, but concurrent use with opioids remained low over time.
- 20 May 2026
- Published by Wiley in Health Services Research
- Vol. 61 (3) , e70133
Gabapentinoid Polypharmacy Among Medicare Beneficiaries During the Poststroke Recovery Period
Objective: To describe patterns of gabapentinoid (Gabapentin and Pregabalin) use and concurrent use with other central nervous system (CNS) acting pain medications (opioids and benzodiazepines) among US Medicare beneficiaries following acute ischemic stroke (AIS). Study Setting and Design: We analyzed new outpatient gabapentinoid prescriptions in older stroke survivors between 2009 and 2022. We calculated the percent of new gabapentinoid initiators within 6 months of stroke discharge and analyzed concurrent pain medications prescribed within 30 days of gabapentinoid initiation. We presented trends and geographic patterns standardized by age, discharge destination, and modified Rankin Scale (mRS) to control for variations in the sample composition by age and stroke severity over time. Data Sources and Analytic Sample: We analyzed a 20% sample of US Medicare beneficiaries aged 65 years or older who were hospitalized for AIS. We included those who met Medicare enrollment criteria, had no prior stroke, no prior gabapentinoid use within 6 months, and were discharged home within 30 days of hospitalization. Principal Findings: Among 153,728 stroke survivors, 4.9% received new gabapentinoid prescriptions within 6 months postdischarge. Of the 7595 gabapentinoid initiators, 1579 (21%) had concurrent opioid and 653 (8.6%) had concurrent benzodiazepine prescriptions. In the sample, the median age was 78 years (Quartile Range: 72–84), 55% were female, and 81% were non‐Hispanic White. The standardized percentage of gabapentinoid initiators increased from 3.8% in 2009 to 5.9% in 2022 (crude: 3.6% in 2009 to 5.8% in 2022). Despite increases in the number of gabapentinoid initiators, the percentage of concurrent opioid users remained low over time, around 1% of the study population. We observed variation in gabapentinoid initiation and concurrent use with opioids by geography. Conclusions: From 2009 to 2022, poststroke gabapentinoid use increased in older adults, but concurrent use with opioids remained low over time.
- Open Access
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e046583
Treatment Patterns of Antiseizure Medication for Poststroke Prophylaxis Among Older Adults
Background: Antiseizure medications are commonly prescribed for poststroke seizures, yet long‐term use lacks clear clinical guidance. We examined medication treatment patterns among older adults who initiated levetiracetam, the most frequently prescribed antiseizure medication, within 30 days after an acute ischemic stroke discharge. Methods: We analyzed a national 20% random sample of US Medicare beneficiaries aged ≥65 years, who were hospitalized for a first acute ischemic stroke between 2009 and 2021 and initiated levetiracetam within 30 days of discharge. To analyze time‐varying Levetiracetam treatment patterns over the first year after initiation, we calculated an adjusted proportion of days covered that accounts for prescription overlap, hospitalization, and non‐persistence. Adherence to levetiracetam treatment strategy was defined as having a proportion of days covered ≥80%. A latent‐class mixed model on proportion of days covered trajectories was applied to identify and characterize different treatment patterns, adjusting for clinical factors. Results: In our sample of 1697 levetiracetam initiators, the mean age was 77.5 years, and 58% were women. The latent‐class mixed model on proportion of days covered trajectories identified 3 distinct levetiracetam treatment patterns: (1) 907 patients (53%) were nonadherent to treatment after 2 months, (2) 99 patients (6%) were nonadherent to treatment after 10 months, and (3) 691 patients (41%) remained consistently adherent to treatment for at least 1 year. White patients and women were more likely to be adherent to the levetiracetam treatment strategy. Conclusions: Approximately 41% of older adults remained consistently adherent to the levetiracetam treatment strategy within a year after outpatient initiation, with race and sex significantly associated with adherence‐to‐treatment probabilities.
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e046583
Open AccessTreatment Patterns of Antiseizure Medication for Poststroke Prophylaxis Among Older Adults
Background: Antiseizure medications are commonly prescribed for poststroke seizures, yet long‐term use lacks clear clinical guidance. We examined medication treatment patterns among older adults who initiated levetiracetam, the most frequently prescribed antiseizure medication, within 30 days after an acute ischemic stroke discharge. Methods: We analyzed a national 20% random sample of US Medicare beneficiaries aged ≥65 years, who were hospitalized for a first acute ischemic stroke between 2009 and 2021 and initiated levetiracetam within 30 days of discharge. To analyze time‐varying Levetiracetam treatment patterns over the first year after initiation, we calculated an adjusted proportion of days covered that accounts for prescription overlap, hospitalization, and non‐persistence. Adherence to levetiracetam treatment strategy was defined as having a proportion of days covered ≥80%. A latent‐class mixed model on proportion of days covered trajectories was applied to identify and characterize different treatment patterns, adjusting for clinical factors. Results: In our sample of 1697 levetiracetam initiators, the mean age was 77.5 years, and 58% were women. The latent‐class mixed model on proportion of days covered trajectories identified 3 distinct levetiracetam treatment patterns: (1) 907 patients (53%) were nonadherent to treatment after 2 months, (2) 99 patients (6%) were nonadherent to treatment after 10 months, and (3) 691 patients (41%) remained consistently adherent to treatment for at least 1 year. White patients and women were more likely to be adherent to the levetiracetam treatment strategy. Conclusions: Approximately 41% of older adults remained consistently adherent to the levetiracetam treatment strategy within a year after outpatient initiation, with race and sex significantly associated with adherence‐to‐treatment probabilities.
- Open Access
Post-Discharge Anti-Seizure Medication Use Improves Post-Stroke Survival: An Emulated Target Trial in Older Adults
Objective: Levetiracetam is commonly prescribed for seizure prophylaxis after acute ischemic stroke (AIS) and often continued beyond discharge. While its short-term effectiveness for preventing post-stroke seizures is established, it is unclear whether prolonged use improves survival, particularly in older adults. We estimated the effect of continued levetiracetam use on 90-day mortality among Medicare beneficiaries after AIS. Methods: Using Traditional Medicare claims data (2008-2021), we identified beneficiaries aged ≥66 years hospitalized for AIS who initiated outpatient levetiracetam within 90 days of discharge. After one month of continued post-stroke use of levetiracetam (start of follow-up), we compared 90-day mortality between patients with a new levetiracetam dispensation within a 14-day grace period post-follow up and those without one. We performed cloning, censoring and weighting to address immortal time bias and estimated standardized mortality risks, risk differences, and 95% confidence intervals (CI). Results: Among 3,212 eligible beneficiaries, 1,779 (55.4%) received a new levetiracetam dispensation within the 14-day grace period. Median age was 76 years (IQR 70-83); 57.8% were female. After adjustment for demographics, hospitalization characteristics, timing of initiation, and comorbidities, continued use was associated with lower 90–day mortality than discontinuation (53 vs 62 deaths per 1,000; risk difference −9 per 1,000; 95% CI: (−12,−5)). The reduction was observed primarily among patients aged ≥75 years. Significance: Among older Medicare beneficiaries who initiated levetiracetam after AIS, continued outpatient use was associated with modestly lower 90–day mortality, particularly in those aged ≥75 years. These findings suggest potential benefits of levetiracetam continuation beyond the immediate post-stroke period.
Open AccessPost-Discharge Anti-Seizure Medication Use Improves Post-Stroke Survival: An Emulated Target Trial in Older Adults
Objective: Levetiracetam is commonly prescribed for seizure prophylaxis after acute ischemic stroke (AIS) and often continued beyond discharge. While its short-term effectiveness for preventing post-stroke seizures is established, it is unclear whether prolonged use improves survival, particularly in older adults. We estimated the effect of continued levetiracetam use on 90-day mortality among Medicare beneficiaries after AIS. Methods: Using Traditional Medicare claims data (2008-2021), we identified beneficiaries aged ≥66 years hospitalized for AIS who initiated outpatient levetiracetam within 90 days of discharge. After one month of continued post-stroke use of levetiracetam (start of follow-up), we compared 90-day mortality between patients with a new levetiracetam dispensation within a 14-day grace period post-follow up and those without one. We performed cloning, censoring and weighting to address immortal time bias and estimated standardized mortality risks, risk differences, and 95% confidence intervals (CI). Results: Among 3,212 eligible beneficiaries, 1,779 (55.4%) received a new levetiracetam dispensation within the 14-day grace period. Median age was 76 years (IQR 70-83); 57.8% were female. After adjustment for demographics, hospitalization characteristics, timing of initiation, and comorbidities, continued use was associated with lower 90–day mortality than discontinuation (53 vs 62 deaths per 1,000; risk difference −9 per 1,000; 95% CI: (−12,−5)). The reduction was observed primarily among patients aged ≥75 years. Significance: Among older Medicare beneficiaries who initiated levetiracetam after AIS, continued outpatient use was associated with modestly lower 90–day mortality, particularly in those aged ≥75 years. These findings suggest potential benefits of levetiracetam continuation beyond the immediate post-stroke period.
- Open Access
Gabapentinoid Use among Medicare Beneficiaries during the Post-Stroke Recovery Period
Background Most studies of gabapentinoid prescribing trends have focused on younger, commercially insured populations. Patterns among vulnerable groups, including older stroke survivors, remain poorly characterized. We described patterns of gabapentinoid initiation among Medicare beneficiaries following acute ischemic stroke (AIS). Methods We analyzed claims data from a 20% sample of U.S. Medicare beneficiaries aged ≥ 65 years hospitalized for AIS between 2009 and 2022. We included individuals enrolled in traditional Medicare for ≥ 12 months before hospitalization, without prior stroke during this interval, and discharged home or to an inpatient destination for ≤30 days. After excluding those with gabapentinoid use before stroke, we analyzed outpatient gabapentin prescriptions six months after stroke discharge by demographic and clinical characteristics. We calculated the percentage of gabapentinoid initiators by year and U.S. census division, standardized by age, discharge destination, and modified Rankin Score (mRS). Results Among 153,728 Medicare stroke survivors who had not previously been prescribed a gabapentinoid in the 6 months before hospitalization, 4.9% received new prescriptions within 6 months after discharge. The median age was 78 years (Quartile Range: 72 - 84), 55% were female, and 81% were Non-Hispanic White. The crude percentage of gabapentinoid initiators increased from 3.6% in 2009 to 5.8% in 2022. The standardized percentages were 3.8% in 2009 and 5.9% in 2022. We reported a 2.1 percentage point difference in gabapentinoid initiation between U.S. census divisions, with the lowest percentage in the New England Division (3.9%) and the highest in the West South Central Division (6.0%). After standardization, the percentage point difference was 1.9% between the highest and lowest U.S. division. Conclusion The percentage of U.S. Medicare stroke survivors initiating gabapentinoid increased from 2009 to 2022. We also identified geographic variation, with the highest initiation percentage in the West South Central and the lowest in the New England U.S. Division. Twitter: @MGHValue
Open AccessGabapentinoid Use among Medicare Beneficiaries during the Post-Stroke Recovery Period
Background Most studies of gabapentinoid prescribing trends have focused on younger, commercially insured populations. Patterns among vulnerable groups, including older stroke survivors, remain poorly characterized. We described patterns of gabapentinoid initiation among Medicare beneficiaries following acute ischemic stroke (AIS). Methods We analyzed claims data from a 20% sample of U.S. Medicare beneficiaries aged ≥ 65 years hospitalized for AIS between 2009 and 2022. We included individuals enrolled in traditional Medicare for ≥ 12 months before hospitalization, without prior stroke during this interval, and discharged home or to an inpatient destination for ≤30 days. After excluding those with gabapentinoid use before stroke, we analyzed outpatient gabapentin prescriptions six months after stroke discharge by demographic and clinical characteristics. We calculated the percentage of gabapentinoid initiators by year and U.S. census division, standardized by age, discharge destination, and modified Rankin Score (mRS). Results Among 153,728 Medicare stroke survivors who had not previously been prescribed a gabapentinoid in the 6 months before hospitalization, 4.9% received new prescriptions within 6 months after discharge. The median age was 78 years (Quartile Range: 72 - 84), 55% were female, and 81% were Non-Hispanic White. The crude percentage of gabapentinoid initiators increased from 3.6% in 2009 to 5.8% in 2022. The standardized percentages were 3.8% in 2009 and 5.9% in 2022. We reported a 2.1 percentage point difference in gabapentinoid initiation between U.S. census divisions, with the lowest percentage in the New England Division (3.9%) and the highest in the West South Central Division (6.0%). After standardization, the percentage point difference was 1.9% between the highest and lowest U.S. division. Conclusion The percentage of U.S. Medicare stroke survivors initiating gabapentinoid increased from 2009 to 2022. We also identified geographic variation, with the highest initiation percentage in the West South Central and the lowest in the New England U.S. Division. Twitter: @MGHValue
Choice of antiseizure medications and associated outcomes in Medicare beneficiaries after acute ischemic stroke
Objective: We examined choice of outpatient epilepsy‐specific antiseizure medication (ESM) after a stroke discharge and outcomes in a sample of US older adults. Methods: In this matched cohort study, we analyzed a 20% sample of US Medicare beneficiaries aged 65 years and older hospitalized for acute ischemic stroke (AIS) between 2009 and 2021 who were discharged home. Individuals met insurance coverage criteria and were not taking ESM before hospitalization. We matched individuals on days from discharge to ESM initiation. Individuals who initiated ESMs other than levetiracetam within 30 days of discharge ( n = 229) were matched to levetiracetam initiators ( n = 687). We did not include antiseizure medications used for treatment of pain or psychiatric disorders such as gabapentin and benzodiazepines. We investigated the time to seizurelike events, emergency department (ED) visits, and readmissions using a semicompeting risk framework. Results: The matched cohort of 916 ESM initiators had a median age of 73 years (interquartile range = 69–81) and was 57% female and 71% non‐Hispanic White. Using the semicompeting risk framework, those who received other ESM had a 37% lower hazard of seizurelike events compared to those receiving levetiracetam, given that death had not occurred (hazard ratio = .63, 95% confidence interval [CI] = .43–.91). Among other ESM initiators, the hazard of ED visits and hospital readmissions, given that death had not occurred, did not differ significantly from initiating levetiracetam (hazard ratios = 1.00 [95% CI = .80–1.25] and .98 [95% CI = .75–1.28], respectively). Significance: In a sample of US Medicare beneficiaries hospitalized for AIS and discharged home, initiating levetiracetam in the outpatient setting was associated with a higher risk of seizurelike events compared to other ESMs. However, there remains a possibility of residual confounding by indication, as individuals with greater risk of seizures may have been started on levetiracetam. We did not observe significant differences in the risk of ED visits or readmissions, suggesting comparable safety profiles in broader clinical outcomes.
Choice of antiseizure medications and associated outcomes in Medicare beneficiaries after acute ischemic stroke
Objective: We examined choice of outpatient epilepsy‐specific antiseizure medication (ESM) after a stroke discharge and outcomes in a sample of US older adults. Methods: In this matched cohort study, we analyzed a 20% sample of US Medicare beneficiaries aged 65 years and older hospitalized for acute ischemic stroke (AIS) between 2009 and 2021 who were discharged home. Individuals met insurance coverage criteria and were not taking ESM before hospitalization. We matched individuals on days from discharge to ESM initiation. Individuals who initiated ESMs other than levetiracetam within 30 days of discharge ( n = 229) were matched to levetiracetam initiators ( n = 687). We did not include antiseizure medications used for treatment of pain or psychiatric disorders such as gabapentin and benzodiazepines. We investigated the time to seizurelike events, emergency department (ED) visits, and readmissions using a semicompeting risk framework. Results: The matched cohort of 916 ESM initiators had a median age of 73 years (interquartile range = 69–81) and was 57% female and 71% non‐Hispanic White. Using the semicompeting risk framework, those who received other ESM had a 37% lower hazard of seizurelike events compared to those receiving levetiracetam, given that death had not occurred (hazard ratio = .63, 95% confidence interval [CI] = .43–.91). Among other ESM initiators, the hazard of ED visits and hospital readmissions, given that death had not occurred, did not differ significantly from initiating levetiracetam (hazard ratios = 1.00 [95% CI = .80–1.25] and .98 [95% CI = .75–1.28], respectively). Significance: In a sample of US Medicare beneficiaries hospitalized for AIS and discharged home, initiating levetiracetam in the outpatient setting was associated with a higher risk of seizurelike events compared to other ESMs. However, there remains a possibility of residual confounding by indication, as individuals with greater risk of seizures may have been started on levetiracetam. We did not observe significant differences in the risk of ED visits or readmissions, suggesting comparable safety profiles in broader clinical outcomes.
- Open Access
Choice of Epilepsy Anti-Seizure Medications and Associated Outcomes in Medicare Beneficiaries
Background: The lack of specific guidelines for seizure treatment after acute ischemic stroke (AIS), makes the choice of an appropriate anti-seizure medication choice a challenge for providers because each drug may have different adverse effects and outcomes. Methods: In this retrospective matched cohort study, we analyzed a 20% sample of U.S. Medicare beneficiaries aged 65 and over hospitalized for a first acute ischemic stroke (AIS) between 2009-2021 who were discharged home. We included individuals who were enrolled in Medicare hospital, medical and prescription drug insurance for 12 months prior to hospitalization and were not taking epilepsy-specific anti-seizure medication (ESM) prior to hospitalization. We matched individuals on days from discharge to ESM initiation. Individuals who initiated ESMs other than Levetiracetam, i.e. Lamotrigine, Carbamazepine, Oxcarbazepine within 30 days of discharge (N = 229) were matched to Levetiracetam initiators (N =687). We investigated the time to seizure-like events, emergency department (ED) visits, and re-hospitalizations with a follow-up of 180 days after initiation using a semi-competing risk framework. We estimated the average treatment effect among the treated i.e. those who received other ESMs. Results: The matched cohort of 916 ESM initiators had a median age of 74 (IQR 69, 82) and was 57% female and 71% Non-Hispanic White. Using the semi-competing risk framework, those who received other ESM had a 37% lower hazard of seizure-like events compared to receiving LEV, given that death had not occurred, hazard ratio 0.63 (95% CI: 0.43, 0.91). Among those who initiated ESMs other than Levetiracetam, the hazard of ED visits and hospitalizations, given that death had not occurred, did not different significantly from initiating Levetiracetam; hazard ratios 1.00 (95% CI: 0.80, 1.25) and 0.98 (95% CI: 0.75, 1.28), respectively. Conclusion: In a sample of Medicare beneficiaries hospitalized for acute ischemic stroke and discharged home, initiating Levetiracetam in the outpatient setting was associated with a higher risk of seizure-like events compared to other ESMs. However, no significant differences were observed in the incidence of ED visits or hospitalizations, suggesting comparable safety profiles in these broader clinical outcomes.
Open AccessChoice of Epilepsy Anti-Seizure Medications and Associated Outcomes in Medicare Beneficiaries
Background: The lack of specific guidelines for seizure treatment after acute ischemic stroke (AIS), makes the choice of an appropriate anti-seizure medication choice a challenge for providers because each drug may have different adverse effects and outcomes. Methods: In this retrospective matched cohort study, we analyzed a 20% sample of U.S. Medicare beneficiaries aged 65 and over hospitalized for a first acute ischemic stroke (AIS) between 2009-2021 who were discharged home. We included individuals who were enrolled in Medicare hospital, medical and prescription drug insurance for 12 months prior to hospitalization and were not taking epilepsy-specific anti-seizure medication (ESM) prior to hospitalization. We matched individuals on days from discharge to ESM initiation. Individuals who initiated ESMs other than Levetiracetam, i.e. Lamotrigine, Carbamazepine, Oxcarbazepine within 30 days of discharge (N = 229) were matched to Levetiracetam initiators (N =687). We investigated the time to seizure-like events, emergency department (ED) visits, and re-hospitalizations with a follow-up of 180 days after initiation using a semi-competing risk framework. We estimated the average treatment effect among the treated i.e. those who received other ESMs. Results: The matched cohort of 916 ESM initiators had a median age of 74 (IQR 69, 82) and was 57% female and 71% Non-Hispanic White. Using the semi-competing risk framework, those who received other ESM had a 37% lower hazard of seizure-like events compared to receiving LEV, given that death had not occurred, hazard ratio 0.63 (95% CI: 0.43, 0.91). Among those who initiated ESMs other than Levetiracetam, the hazard of ED visits and hospitalizations, given that death had not occurred, did not different significantly from initiating Levetiracetam; hazard ratios 1.00 (95% CI: 0.80, 1.25) and 0.98 (95% CI: 0.75, 1.28), respectively. Conclusion: In a sample of Medicare beneficiaries hospitalized for acute ischemic stroke and discharged home, initiating Levetiracetam in the outpatient setting was associated with a higher risk of seizure-like events compared to other ESMs. However, no significant differences were observed in the incidence of ED visits or hospitalizations, suggesting comparable safety profiles in these broader clinical outcomes.
- Open Access
- 1 February 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (1) , e200403
Barriers to Medication Adherence in People Living With Epilepsy
Epilepsy affects approximately 1.2% of the US population, resulting in 3.4 million Americans with active epilepsy. Antiseizure medication (ASM) is considered the mainstay of treatment, effective for two-thirds of people with epilepsy (PWE), while at least one-third experience drug-resistant epilepsy. A significant percentage of PWE who are treated with ASMs report nonadherence to this type of medication, leading to potentially preventable seizures and the potential for being inappropriately classified as having drug-resistant epilepsy. Ongoing seizures are associated with increased morbidity, mortality, and health care costs, among other consequences. Recognizing when PWE struggle with ASM adherence is essential for creating effective interventions and prevention strategies to improve patient outcomes. As part of the Epilepsy Learning Healthcare System Registry, we collected data from 2020 through 2023 from 4,917 individuals seen at 8 epilepsy clinics in the United States. In this cross-sectional study, we used logistic regression analysis to examine the relationship between patient-reported seizure control (or provider-reported seizure control for some sites) and endorsed barriers to medication adherence. In addition, we explored potential associations with demographic variables such as sex, race, and ethnicity. The data analysis was conducted using R version 2023.06.1 + 524. Overall, 18.4% (893/4,848) reported adherence barriers and 37.7% (1,447/3,834) reported seizure control, defined as no seizures for the preceding 12 months or longer. The most prevalent barriers were forgetting to take ASMs (48.2%), experiencing ASM side effects (29.2%), and feeling as if the ASMs were not helping in controlling seizures (21.3%). The PWE who reported adherence barriers had 0.6 lower odds of having seizure control compared with those who did not report barriers (95% CI 0.4–0.7) and 0.6 lower odds of having seizure control after adjusting for race, ethnicity, and sex (95% CI 0.5–0.7). We observed significant barriers to medication adherence and inadequate seizure control among adult PWE across 8 centers in the United States. This study suggests that PWE might benefit from standardized screening for adherence barriers with behavioral strategies to address these barriers offered during clinical encounters to personalize care.
- 1 February 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (1) , e200403
Open AccessBarriers to Medication Adherence in People Living With Epilepsy
Epilepsy affects approximately 1.2% of the US population, resulting in 3.4 million Americans with active epilepsy. Antiseizure medication (ASM) is considered the mainstay of treatment, effective for two-thirds of people with epilepsy (PWE), while at least one-third experience drug-resistant epilepsy. A significant percentage of PWE who are treated with ASMs report nonadherence to this type of medication, leading to potentially preventable seizures and the potential for being inappropriately classified as having drug-resistant epilepsy. Ongoing seizures are associated with increased morbidity, mortality, and health care costs, among other consequences. Recognizing when PWE struggle with ASM adherence is essential for creating effective interventions and prevention strategies to improve patient outcomes. As part of the Epilepsy Learning Healthcare System Registry, we collected data from 2020 through 2023 from 4,917 individuals seen at 8 epilepsy clinics in the United States. In this cross-sectional study, we used logistic regression analysis to examine the relationship between patient-reported seizure control (or provider-reported seizure control for some sites) and endorsed barriers to medication adherence. In addition, we explored potential associations with demographic variables such as sex, race, and ethnicity. The data analysis was conducted using R version 2023.06.1 + 524. Overall, 18.4% (893/4,848) reported adherence barriers and 37.7% (1,447/3,834) reported seizure control, defined as no seizures for the preceding 12 months or longer. The most prevalent barriers were forgetting to take ASMs (48.2%), experiencing ASM side effects (29.2%), and feeling as if the ASMs were not helping in controlling seizures (21.3%). The PWE who reported adherence barriers had 0.6 lower odds of having seizure control compared with those who did not report barriers (95% CI 0.4–0.7) and 0.6 lower odds of having seizure control after adjusting for race, ethnicity, and sex (95% CI 0.5–0.7). We observed significant barriers to medication adherence and inadequate seizure control among adult PWE across 8 centers in the United States. This study suggests that PWE might benefit from standardized screening for adherence barriers with behavioral strategies to address these barriers offered during clinical encounters to personalize care.
- 1 February 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (1) , e200379
Health Disparities Among Sexual and Gender Minority People Living With Epilepsy
Visibility of sexual and gender minority (SGM) people has been steadily increasing over the recent years; however, little is known about the distinct seizure and mental health characteristics among SGM people with epilepsy. In this study, we describe these characteristics among SGM subgroups. Data on demographics, seizure metrics, mental health, and quality of life were collected using patient-reported questionnaires gathered at first epilepsy clinic visits as part of routine clinical care from January 2019 to September 2023 at Massachusetts General Hospital. SGM people were defined as people who completed both sexual orientation and gender identity questionnaires and reported a sexual orientation other than heterosexual and/or a gender identity other than cisgender. Seizure control was defined as 1 year or more without experiencing seizures. Anxiety, depression, and quality-of-life data were collected through ordinal scales (GAD-7, PHQ-9, and PROMIS 10, respectively). Descriptive statistics were used to compare data between groups. No association test was performed because of the descriptive nature of this study. From 4,046 first-visit questionnaires, 2,166 (53.53%) had sexual orientation and gender identity information, with 143 (6.6%) of these respondents identified as SGM. Seizure control was present in 27 (65.85%) and 401 (62.95%) heterosexual cisgender respondents. Median values of SGM and heterosexual cisgender respondents were 5 (interquartile range [IQR] 8) and 3 (IQR 6) for PHQ-9 (depression), 4 (IQR 7) and 3 (IQR 10) for GAD-7 (anxiety), 41.1 (IQR 14.5) and 45.8 (IQR 14.5) for PROMIS-10-Mental, and 47.7 (IQR 11.8) and 50.8 (IQR 15.4) for PROMIS-10-Physical, respectively. This study provides one of the first overviews of distinct epilepsy, mental health, and quality-of-life metrics among SGM people. The low proportion of survey responses regarding sexual orientation and gender identity fields indicate the need for improved data collection methods in epilepsy clinics.
- 1 February 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (1) , e200379
Health Disparities Among Sexual and Gender Minority People Living With Epilepsy
Visibility of sexual and gender minority (SGM) people has been steadily increasing over the recent years; however, little is known about the distinct seizure and mental health characteristics among SGM people with epilepsy. In this study, we describe these characteristics among SGM subgroups. Data on demographics, seizure metrics, mental health, and quality of life were collected using patient-reported questionnaires gathered at first epilepsy clinic visits as part of routine clinical care from January 2019 to September 2023 at Massachusetts General Hospital. SGM people were defined as people who completed both sexual orientation and gender identity questionnaires and reported a sexual orientation other than heterosexual and/or a gender identity other than cisgender. Seizure control was defined as 1 year or more without experiencing seizures. Anxiety, depression, and quality-of-life data were collected through ordinal scales (GAD-7, PHQ-9, and PROMIS 10, respectively). Descriptive statistics were used to compare data between groups. No association test was performed because of the descriptive nature of this study. From 4,046 first-visit questionnaires, 2,166 (53.53%) had sexual orientation and gender identity information, with 143 (6.6%) of these respondents identified as SGM. Seizure control was present in 27 (65.85%) and 401 (62.95%) heterosexual cisgender respondents. Median values of SGM and heterosexual cisgender respondents were 5 (interquartile range [IQR] 8) and 3 (IQR 6) for PHQ-9 (depression), 4 (IQR 7) and 3 (IQR 10) for GAD-7 (anxiety), 41.1 (IQR 14.5) and 45.8 (IQR 14.5) for PROMIS-10-Mental, and 47.7 (IQR 11.8) and 50.8 (IQR 15.4) for PROMIS-10-Physical, respectively. This study provides one of the first overviews of distinct epilepsy, mental health, and quality-of-life metrics among SGM people. The low proportion of survey responses regarding sexual orientation and gender identity fields indicate the need for improved data collection methods in epilepsy clinics.